Feeds › Ownership stakes (13D / 13G)
Ownership stakes (13D / 13G)
Investors who own more than 5% of a company, from activists (13D) to passive holders (13G).
About this data
- What it is
- An investor who owns more than 5% of a public company must say so. Investors who may try to influence the company, such as activists, file the longer Schedule 13D; passive holders file the shorter Schedule 13G.
- Who files it
- The investor, within days of crossing 5%, and again whenever the stake changes materially.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- 13G filings are far more common than 13D. A 13D usually means the investor intends to push for changes, so it tends to get more attention.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Filings per day, last 30 days
13D (activist) 13G (passive)
Latest ownership filings
Showing: ticker VREOF
| Filed | ScheduleBoth report a stake of more than 5%. A 13D is filed by investors who may try to influence the company, such as activists; a 13G by passive holders. | Company | Investor | Shares | % of shares | Filing |
|---|---|---|---|---|---|---|
| Nov 10, 2026 | SCHEDULE 13D/A (amended) | VREOF Vireo Growth Inc. | Ca Co SPV, LLC | 7.47M | 14.5% | SCHEDULE 13D/A ↗ |
| Nov 10, 2026 | SCHEDULE 13D/A (amended) | VREOF Vireo Growth Inc. | Chicago Atlantic Equity Fund, LLC | 7.47M | 14.5% | SCHEDULE 13D/A ↗ |
| Nov 10, 2026 | SCHEDULE 13D/A (amended) | VREOF Vireo Growth Inc. | Chicago Atlantic Credit Company, LLC | 7.47M | 14.5% | SCHEDULE 13D/A ↗ |
| Nov 10, 2026 | SCHEDULE 13D/A (amended) | VREOF Vireo Growth Inc. | Chicago Atlantic Opportunity Finance, LLC | 7.47M | 14.5% | SCHEDULE 13D/A ↗ |
| Nov 10, 2026 | SCHEDULE 13D/A (amended) | VREOF Vireo Growth Inc. | Chicago Atlantic Credit Opportunities, LLC | 7.47M | 14.5% | SCHEDULE 13D/A ↗ |
| Nov 10, 2026 | SCHEDULE 13D/A (amended) | VREOF Vireo Growth Inc. | Chicago Atlantic Opportunity GP, LLC | 7.47M | 14.5% | SCHEDULE 13D/A ↗ |
| Nov 10, 2026 | SCHEDULE 13D/A (amended) | VREOF Vireo Growth Inc. | Chicago Atlantic Opportunity Portfolio, LP | 7.47M | 14.5% | SCHEDULE 13D/A ↗ |
| Nov 10, 2026 | SCHEDULE 13D/A (amended) | VREOF Vireo Growth Inc. | Chicago Atlantic Group GP, LLC | 7.47M | 14.5% | SCHEDULE 13D/A ↗ |
| Nov 10, 2026 | SCHEDULE 13D/A (amended) | VREOF Vireo Growth Inc. | Chicago Atlantic Group, LP | 7.47M | 14.5% | SCHEDULE 13D/A ↗ |
| Nov 10, 2026 | SCHEDULE 13D/A (amended) | VREOF Vireo Growth Inc. | Chicago Atlantic GP Holdings, LLC | 7.47M | 14.5% | SCHEDULE 13D/A ↗ |
| Nov 10, 2026 | SCHEDULE 13D/A (amended) | VREOF Vireo Growth Inc. | Chicago Atlantic Manager, LLC | 7.47M | 14.5% | SCHEDULE 13D/A ↗ |
| Nov 10, 2026 | SCHEDULE 13D/A (amended) | VREOF Vireo Growth Inc. | Chicago Atlantic Advisers, LLC | 7.47M | 14.5% | SCHEDULE 13D/A ↗ |
| Sep 19, 2025 | SCHEDULE 13G | VREOF Vireo Growth Inc. | RP Holding, LLC | 59.63M | 6.5% | SCHEDULE 13G ↗ |
| Sep 19, 2025 | SCHEDULE 13G | VREOF Vireo Growth Inc. | Roger Primm | 59.63M | 6.5% | SCHEDULE 13G ↗ |
| Aug 1, 2025 | SCHEDULE 13D | VREOF Vireo Growth Inc. | KCRB LLC | 58.42M | 6.3% | SCHEDULE 13D ↗ |
| Aug 1, 2025 | SCHEDULE 13D | VREOF Vireo Growth Inc. | Ryan Breeden | 59.31M | 6.4% | SCHEDULE 13D ↗ |
| Aug 1, 2025 | SCHEDULE 13D | VREOF Vireo Growth Inc. | Keith Capurro | 60.20M | 6.5% | SCHEDULE 13D ↗ |
| Jul 28, 2025 | SCHEDULE 13G | VREOF Vireo Growth Inc. | GEP Ventures, LLC | 59.63M | 6.5% | SCHEDULE 13G ↗ |
| Jul 28, 2025 | SCHEDULE 13G | VREOF Vireo Growth Inc. | Gary Primm | 59.63M | 6.5% | SCHEDULE 13G ↗ |
| May 23, 2025 | SCHEDULE 13D | VREOF Vireo Growth Inc. | J-Bird Capital LLC | 15.05M | 3.0% | SCHEDULE 13D ↗ |
| May 23, 2025 | SCHEDULE 13D | VREOF Vireo Growth Inc. | Christopher James Jeffery Revocable Trust | 28.32M | 5.6% | SCHEDULE 13D ↗ |
| May 23, 2025 | SCHEDULE 13D | VREOF Vireo Growth Inc. | Christopher Jeffery | 43.37M | 8.6% | SCHEDULE 13D ↗ |
| Apr 22, 2025 | SCHEDULE 13D/A (amended) | VREOF Vireo Growth Inc. | Chicago Atlantic Group GP, LLC | 101.28M | 28.0% | SCHEDULE 13D/A ↗ |
| Apr 22, 2025 | SCHEDULE 13D/A (amended) | VREOF Vireo Growth Inc. | Chicago Atlantic Opportunity GP, LLC | 84.05M | 24.4% | SCHEDULE 13D/A ↗ |
| Apr 22, 2025 | SCHEDULE 13D/A (amended) | VREOF Vireo Growth Inc. | Chicago Atlantic Opportunity Portfolio, LP | 84.05M | 24.4% | SCHEDULE 13D/A ↗ |
| Apr 22, 2025 | SCHEDULE 13D/A (amended) | VREOF Vireo Growth Inc. | Chicago Atlantic Group, LP | 101.28M | 28.0% | SCHEDULE 13D/A ↗ |
| Apr 22, 2025 | SCHEDULE 13D/A (amended) | VREOF Vireo Growth Inc. | Chicago Atlantic GP Holdings, LLC | 132.63M | 36.7% | SCHEDULE 13D/A ↗ |
| Apr 22, 2025 | SCHEDULE 13D/A (amended) | VREOF Vireo Growth Inc. | Chicago Atlantic Manager, LLC | 48.58M | 13.7% | SCHEDULE 13D/A ↗ |
| Apr 22, 2025 | SCHEDULE 13D/A (amended) | VREOF Vireo Growth Inc. | Chicago Atlantic Advisers, LLC | 100.60M | 27.9% | SCHEDULE 13D/A ↗ |
| Jan 10, 2025 | SCHEDULE 13G/A (amended) | VREOF Vireo Growth Inc. | Black Maple Capital Management LP | 4.41M | 1.3% | SCHEDULE 13G/A ↗ |
| Jan 10, 2025 | SCHEDULE 13G/A (amended) | VREOF Vireo Growth Inc. | Barnard Robert James | 11.29M | 3.4% | SCHEDULE 13G/A ↗ |
| Dec 31, 2024 | SCHEDULE 13G | VREOF Vireo Growth Inc. | Ca Pipe SPV, LLC | 32.03M | 8.8% | SCHEDULE 13G ↗ |
32 items, most recent first (up to 50). Every row links to its original filing. Updated Nov 15, 2026, 6:15 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances